Sumitomo Corporation (Sumitomo Shoji Kaisha,Ltd.) (8053) · InitiativeAchieved
Entry into the U.S. generic pharmaceuticals business
First written in FY2018. 1 of 2 entries say "Achieved", first in FY2025-H1. Latest entry: FY2025-H1.
2entries
7years
0from disclosures
How it moved
Same theme, other companies
Entry into and Sale of the U.S. Generic Pharmaceutical BusinessA theme 1 companies write about · 0 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2025-H1AchievedAnnual report
「Asset recycling: Sale of policy-held shares, proceeds recovered from the sale of the U.S. pharmaceuticals business, and other measures」
For the U.S. pharmaceuticals business, the recovery of proceeds from its sale was described as an asset recycling achievement. The business progressed from entry and ownership to the recovery of proceeds through a sale. - FY2018First statedAnnual report
「In the life sciences field, the company entered the generic pharmaceuticals business in the United States, the world’s largest pharmaceutical market.」
The company entered the U.S. generic pharmaceuticals business and identified the promotion of health through the provision of high-quality pharmaceuticals as its objective.